Breaking News, Financial News

Emergent BioSolutions 2Q Financial Results

NARCAN and Smallpox MCM sales drive revenue growth in the quarter.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Emergent 2Q Revenue: $337.9 million (+39%) 2Q Loss: $261.3 million (loss of $56.4 million 2Q22) Comments: Anthrax MCM sales were $21.2 million down 78% reflecting the impact of timing of sales related to CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, and BioThrax (Anthrax Vaccine Adsorbed), partially offset by an increase in sales of Anthrasil.   NARCAN sales were $133.9 million, up 32% primarily driven by higher branded NARCAN sales to U.S. public interest cha...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters